IDO1 and neoplasm: Rather, because immune cells with killing effects were activated by YH29407, which is an IDO1 inhibitor with high pharmacokinetics and pharmacodynamics, the inhibition of CD4+ T cells, which can differentiate into Tregs, may have helped in tumor suppression.